跳至主要内容
临床试验/EUCTR2013-003199-11-BE
EUCTR2013-003199-11-BE进行中(未招募)1 期

Changing the coUrse of cRohn's disease with an Early use of adalimumab: The CURE study. - CURE

GETAID - Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives0 个研究点目标入组 200 人开始时间: 2015年7月27日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Male or female patient aged 18 to 75
  • 2. Patient with early luminal Crohn's disease (less than 24 months since diagnosis),
  • 3. Patient
  • - intolerant to immunosuppressants or steroids, or
  • - primarily not responders to immunosuppressants for at least 3 months [azathioprine: at least 2.5 mg/kg/d; 6-mercaptopurine: at least 1.5 mg/kg/d; methotrexate: 25 mg/week (subcutaneous or intramuscular route)], and/or
  • - not responder to steroids [prednisolone equivalent at least 40 mg/d],
  • - steroid-dependent [unable to reduce corticosteroids below the equivalent of prednisolone 10 mg/d or budesonide < 6 mg/d within 3 months of starting corticosteroids without recurrent active disease, or who have a relapse within 3 months of stopping corticosteroids],
  • 4. Patient with CDAI > 150,
  • 5. Patient with at least one ulcer in at least one affected segment (Magnetic Resonance Imaging (MRI) of gastrointestinal tract or colonoscopy conducted after failure of conventional therapy and within 12 weeks before inclusion in the study or capsule endoscopy ),
  • 6. Patient naïve for all biologics known to be effective for Crohn's Disease
  • 7. Patient whose physician decides to start adalimumab as monotherapy independently from the study protocol,
  • 8. Patient followed in a centre belonging to the GETAID network.
  • 9. Written consent.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 200
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Patient with active complex perianal fistula according to the definition of the
  • American Gastroenterological Association (AGA) [high anal fistula,
  • abscess, proctitis, multiple external openings],
  • - Patient with stoma,
  • -Previous surgical history for Crohn Disease
  • - Pregnant or breastfeeding women, absence of contraception
  • - Patient with any contra-indication to adalimumab.
  • - Patient with any contra-indication to MRI
  • - Minors and people unable to give their consent (because of their physical or mental state).
  • - Subject who has not given his/her consent to participate.
  • - Subject participating in another study.

研究者

发起方
GETAID - Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives

相似试验